Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1226 • ACR Convergence 2021
The Neuro-QOL Upper Extremity Function Scale: New Opportunities to More Reliably and Precisely Measure Self-reported Hand Function and Self-care Activities in People with RA
Susan Bartlett¹, Orit Schieir², Marie-France Valois¹, Janet Pope³, Gilles Boire⁴, Edward Keystone⁵, Diane Tin⁶, Carter Thorne⁷, Carol Hitchon⁸, Louis Bessette⁹, Glen Hazlewood¹⁰, Vivian Bykerk¹¹ and CATCH Investigators¹², ¹McGill University, Montréal, QC, Canada, ²Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, ³University of Western Ontario, London, ON, Canada, ⁴Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁵Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁶The Arthritis Program Research Group, Newmarket, ON, Canada, ⁷Southlake Regional Health Centre, Newmarket, ON, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, ¹⁰University of Calgary, Calgary, AB, Canada, ¹¹Hospital for Special Surgery, New York, NY, ¹²Canadian Early Arthritis Cohort Investigators, Toronto, ON, Canada
Background/Purpose: RA is an inflammatory disease that results in pain and loss of function, especially in the hands and wrists. Brief self-assessment tools that can…
Abstract Number: 1242 • ACR Convergence 2021
Sex Differences in Treatment Response to Three Different Biological Treatments and Corticosteroids in Patients with Early Rheumatoid Arthritis
Kristina Lend¹, Ronald F van Vollenhoven², Jon Lampa³, Merete Hetland⁴, Espen Haavardsholm⁵, Dan Nordström⁶, Michael Nurmohamed⁷, Bjorn Gudbjornsson⁸, Anna Rudin⁹, Mikkel Ostergaard¹⁰, Till Uhlig¹¹, Gerdur Grondal⁸, Kim Hørslev-Petersen¹², Marte S Heiberg⁵, Tuulikki Sokka-Isler¹³, Jos Twisk¹⁴ and Irene van der Horst-Bruinsma¹⁵, ¹Department of Medicine, Rheumatology Unit, The Karolinska Institute, Stockholm, Sweden, ²Amsterdam University Medical Centers, Department of Rheumatology and Clinical Immunology, Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ³Karolinska University Hospital, Department of Medicine, Rheumatology Unit, The Karolinska Institute, Stockholm, Sweden, Stockholm, Sweden, ⁴DANBIO and COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ⁵Diakonhjemmet Hospital, Oslo, Norway, ⁶Division of Internal Medicine and Rheumatology, Helsinki University Hospital, Helsinki, Finland, ⁷Amsterdam University Medical Centers, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ⁸Landspitali University Hospital, University of Iceland, Reykjavik, Iceland, ⁹Rheumatology Clinic, Sahlgrenska University Hospital, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden, ¹⁰Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Glostrup, Denmark, ¹¹Diakonhjemmet Hospital, University of Oslo, Oslo, Norway, ¹²Danish Hospital for Rheumatic Diseases, University of Southern Denmark, Reykjavik, Iceland, Haderslev, Denmark, ¹³University of Eastern Finland, Jyväskylä Central Hospital, Jyväskylä, Finland, ¹⁴Department of Epidemiology and Biostatistics, Amsterdam University Medical Centres, Amsterdam, Netherlands, ¹⁵Department of Rheumatology, VU University Medical Centre, Amsterdam, Netherlands
Background/Purpose: To investigate sex differences in clinical response to three different biological treatments in combination with methotrexate (MTX) versus MTX plus corticosteroids (active conventional treatment;…
Abstract Number: 1385 • ACR Convergence 2021
Overall Survival in Patients with Systemic Autoimmune Diseases Following Lung or Heart-Lung Transplantation at a Single High-Volume Academic Transplant Center: A Comparative Cohort Study
Jason Melehani¹, Shufeng Li², Joshua Mooney³ and Lorinda Chung², ¹Stanford University, San Jose, CA, ²Stanford University, Palo Alto, CA, ³Stanford University, Stanford, CA
Background/Purpose: Lung manifestations of systemic autoimmune diseases are a frequent cause of early death. For many patients, current treatments cannot arrest the inexorable progression to…
Abstract Number: 1533 • ACR Convergence 2021
Comparison of Hospitalization and Mortality Rate in Patients with Different Rheumatic Diseases: A Brazilian Registry Cross-Sectional Analysis
Claudia Marques¹, Ana Paula Reis², Adriana Kakehasi³, Edgard Neto⁴, Marcelo Medeiros Pinheiro⁵, Gecilmara Salviato Pileggi⁶, Gilda Ferreira⁷, Licia Maria Henrique Mota⁸, Odirlei Andre Monticielo⁹, Sandra Lúcia Ribeiro¹⁰, Felipe Omura¹¹, Adriana Marinho¹², Francinne Ribeiro¹³, Laurindo Rocha Jr¹⁴, Ana Silvia Martins¹⁵, Michel Yazbek¹⁶, Mariana Souza¹⁷, Nathália Sacilotto¹⁸, Samuel Shinjo¹⁹, Lilian Valadares²⁰, Ana Silva²¹, Danielle Christine de Brito²², Viviane de Souza²³, Carolina Costa²⁴, Samia Studart²⁵, Antônio Ximenes²⁶ and Ricardo Xavier²⁷, ¹Hospital das Clnicas - Universidade Federal de Pernambuco - UFPE, Recife, Brazil, ²Centro Universitrio de Braslia- UniCEUB, Brasilia, Brazil, ³Federal University of Minas Gerais, Belo Horizonte, Brazil, ⁴UNIFESP, São Paulo, Brazil, ⁵Universidade Federal de São Paulo, São Paulo, Brazil, ⁶FACISB, Ribeirao Preto, Brazil, ⁷Federal University of Minas Gerais, Belo Horizonte, Brazil, ⁸Universidade de Brasília, Brasilia, Brazil, ⁹Serviço de Reumatologia do Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ¹⁰Universidade Federal do Amazonas, Amazonas, Brazil, ¹¹Clinica Omura, São Paulo, Brazil, ¹²FUNDHACRE, Rio Branco, Brazil, ¹³UERJ, Rio de Janeiro, Brazil, ¹⁴Instituto de Medicina Integral Professor Fernando Figueira - IMIP, Recife, Brazil, ¹⁵UFU, Uberlandia, MG, Brazil, ¹⁶UNICAMP, Campinas, Brazil, ¹⁷SCBH, Belo Horizonte, Brazil, ¹⁸Instituto de Assistência Médica ao Servidor Público Estadual, São Paulo, Brazil, ¹⁹Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²⁰HOSPITAL GETULIO VARGAS, Recife, Brazil, ²¹UFG, GOIANIA, Goias, Brazil, ²²UFPB, Joao Pessoa, Brazil, ²³UFJF, JUIZ DE FORA, Brazil, ²⁴UFES, Vitoria, Brazil, ²⁵HOSPITAL GERAL DE FORTALEZA, Fortaleza, Brazil, ²⁶CLINICA CIP, Goiania, Brazil, ²⁷Departamento de Reumatologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
Background/Purpose: The COVID-19 pandemic has brought uncertainties to the rheumatological practice, and despite the large number of publications to date, many questions remain unanswered. One…
Abstract Number: 1657 • ACR Convergence 2021
Comprehensive Assessment of Multimorbidity Burden in a Population-based Cohort of Patients with Rheumatoid Arthritis
Cynthia Crowson¹, Tina Gunderson², Elena Myasoedova², Elizabeth Atkinson², Vanessa Kronzer², Caitrin Coffey² and John Davis², ¹Mayo Clinic, Eyota, MN, ²Mayo Clinic, Rochester, MN
Background/Purpose: Multimorbidity is common in patients with rheumatoid arthritis (RA), and it is associated with poor outcomes. The literature on multimorbidity suffers from numerous definitions…
Abstract Number: 1673 • ACR Convergence 2021
Riding Multiple Waves of Uncertainty: Real World Canadian RA Patient Outcomes over 1 Year of COVID-19 Restrictions
Orit Schieir¹, Susan Bartlett², Marie-France Valois², Louis Bessette³, Gilles Boire⁴, Glen Hazlewood⁵, Carol Hitchon⁶, Edward Keystone⁷, Janet Pope⁸, Diane Tin⁹, Carter Thorne¹⁰, Vivian Bykerk¹¹ and CATCH Investigators¹², ¹Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, ²McGill University, Montréal, QC, Canada, ³Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, ⁴Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁸University of Western Ontario, London, ON, Canada, ⁹The Arthritis Program Research Group, Newmarket, ON, Canada, ¹⁰Southlake Regional Health Centre, Newmarket, ON, Canada, ¹¹Hospital for Special Surgery, New York, NY, ¹²Mt Sinai Hospital, Toronto, ON, Canada
Background/Purpose: During the COVID-19 pandemic, Canadians adults with RA faced considerable uncertainty due to greater risk of infection, hospitalization, changing access to RA medications, and…
Abstract Number: 1689 • ACR Convergence 2021
Safety, Tolerability, Pharmacokinetics, Receptor Occupancy, and Suppression of T-cell-Dependent Antibody Response in a Phase 1 Study with KPL-404, an anti-CD40 Monoclonal Antibody
Manoj Samant¹, Alistair Wheeler², Guang-Liang Jiang¹, Moses Njenga¹, Madeline Spiers¹, Arian Pano¹ and John F Paolini¹, ¹Kiniksa Pharmaceuticals Corp., Lexington, MA, ²Kiniksa Pharmaceuticals, Ltd., Hamilton, Bermuda
Background/Purpose: T-cell priming and T-cell-dependent B-cell responses require an intact cluster of differentiation (CD)40/CD40L pathway. CD40 is expressed on the surface of B-cells, dendritic cells,…
Abstract Number: 1706 • ACR Convergence 2021
Twenty-four-week Follow-up of a Randomized Controlled First-in-Human Trial of the Safety and Efficacy of Neurostimulation with a Miniaturized Vagus Nerve Stimulation Device in Patients with Multidrug-Refractory Rheumatoid Arthritis
Norman Gaylis¹, Mark Genovese², David Sikes³, Alan Kivitz⁴, Diane Horowitz⁵, Charles Peterfy⁶, Yaakov Levine⁷ and David Chernoff⁸, ¹Arthritis and Rheumatic Disease Specialties, Aventura, FL, ²Stanford University, Sunnyvale, CA, ³Florida Medical Clinic, Wesley Chapel, FL, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵Northwell Health, Jericho, NY, ⁶Spire Sciences, Inc., Boca Raton, FL, ⁷SetPoint Medical, Manhassest, NY, ⁸SetPoint Medical, Sausalito, CA
Background/Purpose: Vagus nerve stimulation (VNS) activates innate neuroimmune reflexes that have been shown to reduce pro-inflammatory cytokines and clinical disease activity in subjects with rheumatoid…
Abstract Number: 1917 • ACR Convergence 2021
Sputum TGF-β1 Is Elevated in Subclinical and Clinically Significant Rheumatoid Arthritis-Associated Interstitial Lung Disease and Correlates with Soluble IL-6R Levels
Timothy Wilson¹, Kevin Deane², Joyce Lee¹, Christopher Collora³, Marie Feser³, Mariana Kaplan⁴, Joshua Solomon⁵ and Kristen Demoruelle⁶, ¹University of Colorado, Denver, CO, ²University of Colorado Denver, Denver, CO, ³University of Colorado Denver, Aurora, CO, ⁴National Institutes of Health, Bethesda, MD, ⁵National Jewish Health, Denver, CO, ⁶University of Colorado Anschutz Medical Campus, Aurora, CO
Background/Purpose: Increased levels of transforming growth factor β1 (TGF-β1) in the lung have been implicated in the pathogenesis of several fibrotic lung diseases, but their…
Abstract Number: L04 • ACR Convergence 2020
Influenza Adverse Events in Patients with Rheumatoid Arthritis in the Tofacitinib Clinical Program
Kevin L Winthrop¹, Arne Yndestad², Dan Henrohn³, Hyejin Jo⁴, Sara Marsal⁵, Maria Galindo⁶, Annette Diehl⁷, Andrea B Shapiro⁸ and Stanley B Cohen⁹, ¹Oregon Health & Science University, Portland, OR, ²Pfizer Inc, Oslo, Norway, ³Pfizer Inc, Sollentuna, Sweden, ⁴Syneos Health, Raleigh, NC, ⁵Vall d’Hebron Hospital, Barcelona, Spain, ⁶Rheumatology Unit, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁷Pfizer Inc, Collegeville, PA, ⁸Pfizer Inc, Peapack, NJ, ⁹Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Patients (pts) with RA have increased susceptibility to seasonal influenza and its complications.1 The COVID-19 pandemic highlights the need to understand acute respiratory RNA…
Abstract Number: 0043 • ACR Convergence 2020
Geographical Disparity in Rheumatoid Arthritis Disease Burden Independent of Race/Ethnicity
Gail Kerr¹, Christopher Swearingen², Manuela Pedra-Nobre³, Dianne Wollaston⁴, Sawsan Najmey⁵, Cynthia Lawrence-Elliott⁶, Theresa Lawrence Ford⁶, Sharon Dowell⁷, Heather North⁸, Robin Dore⁹, Soha Dolatabadi¹⁰, Thaila Ramanujam¹¹, Anne Winkler¹², Stacy Kennedy¹³, Ilona Jileaeva¹⁴, Amina Richardson¹⁵, Jeffrey Kaine¹⁶ and Grace Wright¹⁷, ¹Washington DC VA Medical Center, Washington, DC, ²New York University, New York, NY, ³North Jersey Rheumatology Center, Westfield, NJ, ⁴Memorial Advanced Rheumatology, Inc, HOUSTON, TX, ⁵Midstate Rheumatology Center, Freehold, NJ, ⁶North Georgia Rheumatology Group, Lawrenceville, GA, ⁷Howard University, Washington, DC, ⁸Pardee UNC Rheumatology, Hendersonville, NC, ⁹Private practice, Tustin, CA, ¹⁰Soha Dolatabadi, MD, Los Angeles, CA, ¹¹Thaila Ramanujanm. M.D Inc, Santa Cruz, CA, ¹²Cox Medical Center, Springfield, MO, ¹³Rowan Diagnostic Clinic, Concord, NC, ¹⁴Howard University Hospital, Washington, DC, ¹⁵Howard University College of Medicine, Washington, DC, ¹⁶Sarasota Arthritis Center, Sarasota, FL, ¹⁷Association of Women in Rheumatology, New York, NY
Background/Purpose: In the US, health care systems vary, as does cost sharing and access to various RA therapies. However, the burden of RA – a…
Abstract Number: 0132 • ACR Convergence 2020
Prevalence of Osteoporosis and Fragitlity Fractures Is Not Different Between ACPA Positive Patients Compared to ACPA Negative Patients in a Real World Setting, Despite Longer Disease Duration and Glucocorticoid-Treatment
Edgar Wiebe¹, Desiree Freier¹, Dörte Huscher², Gloria Dallagiacoma³, Sandra Hermann¹, Robert Biesen⁴, Gerd Burmester⁵ and Frank Buttgereit⁶, ¹Charité University Medicine Berlin, Dep. of Rheumatology and Clinical Immunology, Berlin, Germany, ²Charité University Medicine Berlin, Dep. of Biometry and Clinical Epidemiology, Berlin, Germany, ³University of Verona, Dep. of Rheumatology, Verona, Italy, ⁴Charité University Medicine, Dep. of Rheumatology and Clinical Immunology, Berlin, ⁵Charité University Hospital Berlin, Berlin, Germany, ⁶Charité University Medicine, Berlin, Germany
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased systemic bone loss, leading to a high risk for hip, vertebral and non-hip, non-vertebral fractures. Especially ACPA…
Abstract Number: 0158 • ACR Convergence 2020
Relationships Between Disease Patterns in RA and Rheumatology Treatment
Kelly O'Neill¹, Kathryne Marks², John Davis³ and Cynthia Crowson⁴, ¹Rheumatoid Patient Foundation, Orlando, FL, ²Rosalind Franklin University of Medicine and Science, North Chicago, IL, ³Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN
Background/Purpose: We previously showed rheumatoid arthritis (RA) patients report diversity in disease activity (DA) patterns that may be associated with treatment response. Patients who describe…
Abstract Number: 0190 • ACR Convergence 2020
Hepatic Steatosis in Rheumatoid Arthritis: Frequency and Disease-Related Contributors
Jun Lee¹, Galina Lagos², Joan Bathon¹ and Jon Giles¹, ¹Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, ²Columbia University Vagelos College of Physicians and Surgeons, New York
Background/Purpose: Nonalcoholic fatty liver disease (NAFLD), a spectrum of disorders characterized by the presence of hepatic steatosis, is the most common liver disorder in western…
Abstract Number: 0206 • ACR Convergence 2020
Fifty-Two Week Outcomes of Biologic-Naïve RA Patients Treated with Subcutaneous Abatacept in Japanese Multicenter Investigational Study (ORIGAMI Study)
Naoto Tamura¹, Eiichi Tanaka², Eisuke Inoue³, Yuri Yoshizawa⁴, Shigeru Matsumoto⁵, Hisashi Yamanaka⁶ and Masayoshi Harigai⁷, ¹Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Bunkyō, Tokyo, Japan, ²Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ³Department of Rheumatology, Tokyo Women’s Medical University School of Medicine; Showa University Research Administration Center, Showa University, Tokyo, Japan, ⁴Bristol-Myers Squibb K.K., Tokyo, Japan, ⁵Ono Pharmaceutical Co., Ltd., Tokyo, Japan, ⁶Department of Rheumatology, Tokyo Women’s Medical University School of Medicine; Rheumatology, Sanno Medical Center, Tokyo, Japan, ⁷Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan
Background/Purpose: Long-term clinical benefit and patient-reported outcomes (PRO) of subcutaneously-injected abatacept (ABA) in patients with RA in a real-world setting are of therapeutic interest. We…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].